Hoffmann-La Roche Inc. received FDA clearance to sell Pegasys, a pegylated interferon for the treatment of hepatitis C, making it the second drug on the market for this disease developed using technology designed to improve circulation time in the body. (BioWorld Today)

Hoffmann-La Roche Inc. received FDA clearance to sell Pegasys, a pegylated interferon for the treatment of hepatitis C, making it the second drug on the market for this disease developed using technology designed to improve circulation time in the body. (BioWorld Today)